Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Cuts Q3 Loss

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it had cut its net loss around 16 percent for the third-quarter, while the firm brought in no revenues for the period.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $1.6 million, or $.05 per share, for the three-month period ended Sept. 30, compared to a net loss of $1.9 million, or $.06 per share, for the third quarter of 2009.

Its R&D spending for the quarter was $1.5 million compared to $1.4 million, while its SG&A expenses were $898,000 compared to $757,000.

"Substantial efforts during 2010 have been directed to planning and initiating a program to substantially increase the value of our discoveries by advancing selected molecules beyond the animal disease model proof of concept, something we have not previously done," Anat Cohen-Dayag, Compugen's president and CEO, said in a statement. "Also, with respect to other commercialization activities, we are currently in discussions with various companies regarding both licensing of certain product candidates and 'discovery on demand' collaborations."

Compugen finished the quarter with $21.4 million in cash, cash equivalents, short-term deposits, and marketable securities.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.